Larissa S May1, Richard E Rothman2, Loren G Miller3, Gillian Brooks4, Mark Zocchi5, Catherine Zatorski4, Andrea F Dugas3, Chelsea E Ware4, Jeanne A Jordan6. 1. 1Emergency Department Antibiotic Stewardship,Department of Emergency Medicine,University of California-Davis,Sacramento,California. 2. 2Department of Emergency Medicine,Johns Hopkins University,Baltimore,Maryland. 3. 3Los Angeles BioMedical Research Center at Harbor-UCLA Medical Center,Torrance,California. 4. 4Department of Emergency Medicine,George Washington University,Washington,DC. 5. 5Office for Clinical Practice Innovation,George Washington University,Washington,DC. 6. 6Department of Epidemiology and Biostatistics,School of Public Health,George Washington University,Washington,DC.
Abstract
OBJECTIVE: To determine whether real-time availability of rapid molecular results of Staphylococcus aureus would impact emergency department clinician antimicrobial selection for adults with cutaneous abscesses. DESIGN: We performed a prospective, randomized controlled trial comparing a rapid molecular test with standard of care culture-based testing. Follow-up telephone calls were made at between 2 and 7 days, 1 month, and 3 months after discharge. SETTING:Two urban, academic emergency departments. PATIENTS: Patients at least 18 years old presenting with a chief complaint of abscess, cellulitis, or insect bite and receiving incision and drainage were eligible. Seven hundred seventy-eight people were assessed for eligibility and 252 met eligibility criteria. METHODS: Clinician antibiotic selection and clinical outcomes were evaluated. An ad hoc outcome of test performance was performed. RESULTS: We enrolled 252 patients and 126 were randomized to receive the rapid test. Methicillin-susceptible S. aureus-positive patients receiving rapid test results were prescribed beta-lactams more often than controls (absolute difference, 14.5% [95% CI, 1.1%-30.1%]) whereas methicillin-resistant S. aureus-positive patients receiving rapid test results were more often prescribed anti-methicillin-resistant S. aureus antibiotics (absolute difference, 21.5% [95% CI, 10.1%-33.0%]). There were no significant differences between the 2 groups in 1-week or 3-month clinical outcomes. CONCLUSION: Availability of rapid molecular test results after incision and drainage was associated with more-targeted antibiotic selection. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01523899.
RCT Entities:
OBJECTIVE: To determine whether real-time availability of rapid molecular results of Staphylococcus aureus would impact emergency department clinician antimicrobial selection for adults with cutaneous abscesses. DESIGN: We performed a prospective, randomized controlled trial comparing a rapid molecular test with standard of care culture-based testing. Follow-up telephone calls were made at between 2 and 7 days, 1 month, and 3 months after discharge. SETTING: Two urban, academic emergency departments. PATIENTS: Patients at least 18 years old presenting with a chief complaint of abscess, cellulitis, or insect bite and receiving incision and drainage were eligible. Seven hundred seventy-eight people were assessed for eligibility and 252 met eligibility criteria. METHODS: Clinician antibiotic selection and clinical outcomes were evaluated. An ad hoc outcome of test performance was performed. RESULTS: We enrolled 252 patients and 126 were randomized to receive the rapid test. Methicillin-susceptible S. aureus-positive patients receiving rapid test results were prescribed beta-lactams more often than controls (absolute difference, 14.5% [95% CI, 1.1%-30.1%]) whereas methicillin-resistant S. aureus-positive patients receiving rapid test results were more often prescribed anti-methicillin-resistant S. aureus antibiotics (absolute difference, 21.5% [95% CI, 10.1%-33.0%]). There were no significant differences between the 2 groups in 1-week or 3-month clinical outcomes. CONCLUSION: Availability of rapid molecular test results after incision and drainage was associated with more-targeted antibiotic selection. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01523899.
Authors: L Renwick; A Hardie; E K Girvan; M Smith; G Leadbetter; E Claas; D Morrison; A P Gibb; J Dave; K E Templeton Journal: Eur J Clin Microbiol Infect Dis Date: 2008-03-21 Impact factor: 3.267
Authors: A Huletsky; R Giroux; V Rossbach; M Gagnon; M Vaillancourt; M Bernier; F Gagnon; K Truchon; M Bastien; F J Picard; A van Belkum; M Ouellette; P H Roy; M G Bergeron Journal: J Clin Microbiol Date: 2004-05 Impact factor: 5.948
Authors: Fred C Tenover; Isabella A Tickler; Victoria M Le; Scott Dewell; Rodrigo E Mendes; Richard V Goering Journal: J Clin Microbiol Date: 2019-10-23 Impact factor: 5.948
Authors: Eili Y Klein; Xianming Zhu; Molly Petersen; Eshan U Patel; Sara E Cosgrove; Aaron A R Tobian Journal: Open Forum Infect Dis Date: 2021-11-22 Impact factor: 4.423
Authors: Larissa S May; Mark Zocchi; Catherine Zatorski; Jeanne A Jordan; Richard E Rothman; Chelsea E Ware; Samantha Eells; Loren Miller Journal: West J Emerg Med Date: 2015-10-20